{"title":"Assays for Modulators of Ryanodine Receptor (RyR)/Ca<sup>2+</sup> Release Channel Activity for Drug Discovery for Skeletal Muscle and Heart Diseases.","authors":"Takashi Murayama, Nagomi Kurebayashi","doi":"10.1002/cpph.71","DOIUrl":null,"url":null,"abstract":"<p><p>The ryanodine receptor (RyR) is a Ca<sup>2+</sup> release channel that is present in the sarcoplasmic reticulum and endoplasmic reticulum (ER) and that plays a central role in excitation-contraction coupling in skeletal and cardiac muscle. Hyperactivation of RyR by genetic mutations or posttranslational modification can cause various skeletal muscle and arrhythmogenic heart diseases. Inhibitors of RyR are therefore expected to be potential drugs for treatment of such diseases. This article describes assays to evaluate RyR channel activity, including an ER Ca<sup>2+</sup> measurement assay that is compatible with high-throughput screening and a [<sup>3</sup> H]-ryanodine binding assay that provides a quantitative measure of RyR channel activity as a second screen for compound hits. © 2019 by John Wiley & Sons, Inc. Basic Protocol 1: [Ca<sup>2+</sup> ]<sub>ER</sub> assay for ryanodine receptor (RyR) channel activity Support Protocol 1: Determination of dose dependence and isoform selectivity of RyR inhibitors using [Ca<sup>2+</sup> ]<sub>ER</sub> assay Basic Protocol 2: [<sup>3</sup> H]-Ryanodine binding assay for RyR channel activity Support Protocol 2: Isolation of microsomes from RyR-expressing HEK293 cells.</p>","PeriodicalId":10871,"journal":{"name":"Current Protocols in Pharmacology","volume":"87 1","pages":"e71"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpph.71","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/cpph.71","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 15
Abstract
The ryanodine receptor (RyR) is a Ca2+ release channel that is present in the sarcoplasmic reticulum and endoplasmic reticulum (ER) and that plays a central role in excitation-contraction coupling in skeletal and cardiac muscle. Hyperactivation of RyR by genetic mutations or posttranslational modification can cause various skeletal muscle and arrhythmogenic heart diseases. Inhibitors of RyR are therefore expected to be potential drugs for treatment of such diseases. This article describes assays to evaluate RyR channel activity, including an ER Ca2+ measurement assay that is compatible with high-throughput screening and a [3 H]-ryanodine binding assay that provides a quantitative measure of RyR channel activity as a second screen for compound hits. © 2019 by John Wiley & Sons, Inc. Basic Protocol 1: [Ca2+ ]ER assay for ryanodine receptor (RyR) channel activity Support Protocol 1: Determination of dose dependence and isoform selectivity of RyR inhibitors using [Ca2+ ]ER assay Basic Protocol 2: [3 H]-Ryanodine binding assay for RyR channel activity Support Protocol 2: Isolation of microsomes from RyR-expressing HEK293 cells.
Ryanodine受体(RyR)/Ca2+释放通道活性调节剂用于骨骼肌和心脏病药物发现的测定。
ryanodine受体(RyR)是一种Ca2+释放通道,存在于肌浆网和内质网(ER)中,在骨骼肌和心肌的兴奋-收缩偶联中起核心作用。基因突变或翻译后修饰导致RyR过度激活可引起各种骨骼肌和心律失常性心脏病。因此,RyR抑制剂有望成为治疗此类疾病的潜在药物。本文描述了评估RyR通道活性的方法,包括与高通量筛选兼容的ER Ca2+测量方法和[3h]-ryanodine结合方法,该方法提供了RyR通道活性的定量测量,作为化合物碰撞的第二筛选方法。©2019 by John Wiley & Sons, Inc。基本方案1:[Ca2+]ER测定RyR受体(RyR)通道活性支持方案1:使用[Ca2+]ER测定RyR抑制剂的剂量依赖性和异构体选择性基本方案2:[3h]-Ryanodine结合测定RyR通道活性支持方案2:从表达RyR的HEK293细胞中分离微粒体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。